ArticleNature2023
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 214 papers.
0numbers the graph read from it
0cells of the map it votes in
214citing papers in PubMed
47.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
214 citing papers in PubMed, 278 citations in OpenAlex.
- CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.Nature medicine · 2024Trial
- Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.Nature communications · 2024Trial
- Article
- Article
- Review
- γδ T cells in colorectal and liver cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- γδ T cells and cancer.The Journal of clinical investigation · 2026Review
- Single-cell landscape of human liver sinusoidal γδ T cells in the context of latent human cytomegalovirus infection.Nature communications · 2026Article
- Review
- Adipocyte-derived LTB4 programs human NKG2AJournal for immunotherapy of cancer · 2026Article
- Viscoelastic Niches Shape γδ T-Cell Phenotype and Effector Function.bioRxiv : the preprint server for biology · 2026Article
- A Microgel-Based Platform for Tunable Expansion and Function of γδ T-cells.bioRxiv : the preprint server for biology · 2026Article
- A DR5/Ligase 3-mediated feedback loop perpetuates immunogenicity in mismatch repair deficient colorectal cancer.Gastroenterology · 2026Article
- Dendritic cell redundancy enables priming of anti-tumor CD4Cancer cell · 2026Article
- Immunological Interactions Between Gammadelta T Cells and West Nile Virus in the Infected Host.Reviews in medical virology · 2026Review
- L-type voltage-gated CaEMBO reports · 2026Article
- Rethinking lymphadenectomy in the immunotherapy era of colorectal cancer: A hypothesis-generating perspective.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Review
- Review
- Killer-cell immunoglobulin-like receptors define a potent effector program in human γδ T cells.JCI insight · 2026Article
154 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
21 authors at 4 institutions in 1 country.
Natasja L de Vries *Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0003-4966-7036
Joris van de Haar *Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Vivien Veninga *Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-5166-5075
Myriam Chalabi *Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-8607-6174
Marieke E IjsselsteijnDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Manon van der PloegDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0001-7150-3068
Jitske van den BulkDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-2056-9478
Dina RuanoDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Jose G van den BergDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
John B HaanenDepartment of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-5884-7704
Laurien J ZeverijnDepartment of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Birgit S GeurtsDepartment of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Gijs F de WitDepartment of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Thomas W BattagliaDepartment of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Hans GelderblomDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0001-9270-8636
Henk M W VerheulDepartment of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands.
Ton N SchumacherDepartment of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-0517-8804
Lodewyk F A WesselsOncode Institute, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-1656-6995
Frits Koning *Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
Noel F C C de Miranda *Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. n.f.de_miranda@lumc.nl.ORCID http://orcid.org/0000-0001-6122-1024
Emile E Voest *Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. e.voest@nki.nl.ORCID http://orcid.org/0000-0001-8249-9586
The Netherlands Cancer Institute · NLLeiden University Medical Center · NLErasmus MC · NLOncode Institute · NL
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB)
Indexed as
Colonic NeoplasmsGenes, MHC Class IHistocompatibility Antigens Class IImmune Checkpoint InhibitorsImmunotherapyReceptors, Antigen, T-Cell, gamma-deltaT-LymphocytesAntigen Presentationbeta 2-MicroglobulinBrain NeoplasmsCell Line, TumorColorectal NeoplasmsCTLA-4 AntigenDNA Mismatch RepairHumansNeoplastic Syndromes, Hereditarybeta 2-MicroglobulinCTLA-4 AntigenCTLA4 protein, humanHistocompatibility Antigens Class IImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-Cell, gamma-deltaReceptors, KIR
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.